The changing role of beta-blocker therapy in patients with cirrhosis

Journal of Hepatology

Volumn 60, Issue 3, 2014, Pages 643-653

  Ge, Phillip S ^a   Runyon, Bruce A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Santa Monica UCLA Medical Center   (United States)

Author keywords

Ascites; Beta blockers; Cirrhosis; Portal hypertension; Variceal hemorrhage

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ASCITES; BLOOD PRESSURE; DRUG EFFECTS; HUMAN; LIVER CIRRHOSIS; MORTALITY; PATHOPHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ASCITES; BLOOD PRESSURE; HUMANS; LIVER CIRRHOSIS;

EID: 84894097292     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.09.016     Document Type: Review

References (100)

1. Y.S. Lim, and W.R. Kim The global impact of hepatic fibrosis and end-stage liver disease Clin Liver Dis 12 2008 733 746
2. S.K. Asrani, J.J. Larson, B. Yawn, T.M. Therneau, and W.R. Kim Underestimation of liver-related mortality in the United States Gastroenterology 145 2013 e372
3. E.E. Powell, W.G. Cooksley, R. Hanson, J. Searle, J.W. Halliday, and L.W. Powell The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years Hepatology 11 1990 74 80
4. G. Vernon, A. Baranova, and Z.M. Younossi Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults Aliment Pharmacol Ther 34 2011 274 285
5. M. Charlton Nonalcoholic fatty liver disease: a review of current understanding and future impact Clin Gastroenterol Hepatol 2 2004 1048 1058
6. A. Monto, J. Alonzo, J.J. Watson, C. Grunfeld, and T.L. Wright Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol Hepatology 36 2002 729 736
7. B. Raynard, A. Balian, D. Fallik, F. Capron, P. Bedossa, and J.C. Chaput et al. Risk factors of fibrosis in alcohol-induced liver disease Hepatology 35 2002 635 638
8. J. Ma, K.V. Lee, and R.S. Stafford Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004 Hypertension 48 2006 846 852
9. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, and J.L. Izzo Jr. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2003 2560 2572
10. S.C. Smith Jr., E.J. Benjamin, R.O. Bonow, L.T. Braun, M.A. Creager, and B.A. Franklin et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation Circulation 124 2011 2458 2473
11. C.W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D.E. Casey Jr., and M.H. Drazner et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 128 2013 e240 319
12. D. Lebrec, T. Poynard, P. Hillon, and J.P. Benhamou Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study N Engl J Med 305 1981 1371 1374
13. J.P. Pascal, and P. Cales Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices N Engl J Med 317 1987 856 861
14. T. Poynard, P. Cales, L. Pasta, G. Ideo, J.P. Pascal, and L. Pagliaro et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group N Engl J Med 324 1991 1532 1538
15. G. Garcia-Tsao, and J. Bosch Management of varices and variceal hemorrhage in cirrhosis N Engl J Med 362 2010 823 832
16. P.C. Hayes, J.M. Davis, J.A. Lewis, and I.A. Bouchier Meta-analysis of value of propranolol in prevention of variceal haemorrhage Lancet 336 1990 153 156
17. T.F. Imperiale, R.W. Klein, and N. Chalasani Cost-effectiveness analysis of variceal ligation vs. beta-blockers for primary prevention of variceal bleeding Hepatology 45 2007 870 878
18. B.M. Spiegel, L. Targownik, G.S. Dulai, H.A. Karsan, and I.M. Gralnek Endoscopic screening for esophageal varices in cirrhosis: is it ever cost effective? Hepatology 37 2003 366 377
19. J.G. Abraldes, I. Tarantino, J. Turnes, J.C. Garcia-Pagan, J. Rodes, and J. Bosch Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis Hepatology 37 2003 902 908
20. R.M. Perez-Ayuso, J.M. Pique, J. Bosch, J. Panes, A. Gonzalez, and R. Perez et al. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis Lancet 337 1991 1431 1434
21. M. Senzolo, E. Cholongitas, P. Burra, G. Leandro, U. Thalheimer, and D. Patch et al. Beta-blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis Liver Int 29 2009 1189 1193
22. T. Serste, C. Melot, C. Francoz, F. Durand, P.E. Rautou, and D. Valla et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites Hepatology 52 2010 1017 1022
23. T. Serste, C. Francoz, F. Durand, P.E. Rautou, C. Melot, and D. Valla et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study J Hepatol 55 2011 794 799
24. B.A. Runyon Care of patients with ascites N Engl J Med 330 1994 337 342
25. R. Planas, S. Montoliu, B. Balleste, M. Rivera, M. Miquel, and H. Masnou et al. Natural history of patients hospitalized for management of cirrhotic ascites Clin Gastroenterol Hepatol 4 2006 1385 1394
26. A. Krag, R. Wiest, A. Albillos, and L.L. Gluud The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease Gut 61 2012 967 969
27. R.W. Schrier, V. Arroyo, M. Bernardi, M. Epstein, J.H. Henriksen, and J. Rodes Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis Hepatology 8 1988 1151 1157
28. S. Moller, F. Bendtsen, and J.H. Henriksen Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis Gastroenterology 109 1995 1917 1925
29. J.H. Henriksen, F. Bendtsen, T.I. Sorensen, C. Stadeager, and H. Ring-Larsen Reduced central blood volume in cirrhosis Gastroenterology 97 1989 1506 1513
30. V. Arroyo, and P. Gines Mechanism of sodium retention and ascites formation in cirrhosis J Hepatol 17 1993 S24 S28
31. L. Ruiz-del-Arbol, A. Monescillo, W. Jimenez, A. Garcia-Plaza, V. Arroyo, and J. Rodes Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis Gastroenterology 113 1997 579 586
32. G. Garcia-Tsao, and J.K. Lim Members of Veterans Affairs Hepatitis CRCP. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Am J Gastroenterol 104 2009 1802 1829
33. P. Hillon, D. Lebrec, C. Munoz, M. Jungers, G. Goldfarb, and J.P. Benhamou Comparison of the effects of a cardioselective and a nonselective beta-blocker on portal hypertension in patients with cirrhosis Hepatology 2 1982 528 531
34. D. Westaby, W.M. Melia, B.R. Macdougall, J.E. Hegarty, A.E. Gimson, and R. Williams B1 selective adrenoreceptor blockade for the long term management of variceal bleeding. A prospective randomised trial to compare oral metoprolol with injection sclerotherapy in cirrhosis Gut 26 1985 421 425
35. T. Poynard, D. Lebrec, P. Hillon, R. Sayegh, J. Bernuau, and S. Naveau et al. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a prospective study of factors associated with rebleeding Hepatology 7 1987 447 451
36. D. Lebrec, T. Poynard, J.P. Capron, P. Hillon, P. Geoffroy, and D. Roulot et al. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. randomized trial J Hepatol 7 1988 118 125
37. G. Ideo, G. Bellati, E. Fesce, and D. Grimoldi Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomized study Hepatology 8 1988 6 9
38. Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients Final report of a multicenter randomized trial. Italian multicenter project for propranolol in prevention of bleeding J Hepatol 9 1989 75 83
39. B. Bernard, D. Lebrec, P. Mathurin, P. Opolon, and T. Poynard Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis Hepatology 25 1997 63 70
40. D.H. Smith, J.M. Kramer, N. Perrin, R. Platt, D.W. Roblin, and K. Lane et al. A randomized trial of direct-to-patient communication to enhance adherence to beta-blocker therapy following myocardial infarction Arch Intern Med 168 2008 477 483 [discussion 483; quiz 447]
41. J.L. Mellinger, and M.L. Volk Multidisciplinary management of patients with cirrhosis: a need for care coordination Clin Gastroenterol Hepatol 11 2013 217 223
42. K. Swedberg Beta-blockers in worsening heart failure: good or bad? Eur Heart J 30 2009 2177 2179
43. D.T. Ko, P.R. Hebert, C.S. Coffey, J.P. Curtis, J.M. Foody, and A. Sedrakyan et al. Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials Arch Intern Med 164 2004 1389 1394
44. M.C. Houston Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome Am Heart J 102 1981 415 430
45. B.M. Psaty, T.D. Koepsell, E.H. Wagner, J.P. LoGerfo, and T.S. Inui The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers JAMA 263 1990 1653 1657
46. R.R. Miller, H.G. Olson, E.A. Amsterdam, and D.T. Mason Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy N Engl J Med 293 1975 416 418
47. J.J. Krukemyer, H. Boudoulas, P.F. Binkley, and J.J. Lima Comparison of hypersensitivity to adrenergic stimulation after abrupt withdrawal of propranolol and nadolol: influence of half-life differences Am Heart J 120 1990 572 579
48. C. Skinner, J. Gaddie, and K.N. Palmer Comparison of effects of metoprolol and propranolol on asthmatic airway obstruction Br Med J 1 1976 504
49. E.D. Frohlich, R.C. Tarazi, and H.P. Dustan Peripheral arterial insufficiency. A complication of beta-adrenergic blocking therapy JAMA 208 1969 2471 2472
50. D.A. Popp, T.F. Tse, S.D. Shah, W.E. Clutter, and P.E. Cryer Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus Diabetes Care 7 1984 243 247
51. R.C. Rosen, J.B. Kostis, and A.W. Jekelis Beta-blocker effects on sexual function in normal males Arch Sex Behav 17 1988 241 255
52. D.T. Ko, P.R. Hebert, C.S. Coffey, A. Sedrakyan, J.P. Curtis, and H.M. Krumholz Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction JAMA 288 2002 351 357
53. R.J. Groszmann, G. Garcia-Tsao, J. Bosch, N.D. Grace, A.K. Burroughs, and R. Planas et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis N Engl J Med 353 2005 2254 2261
54. J.F. Murray, A.M. Dawson, and S. Sherlock Circulatory changes in chronic liver disease Am J Med 24 1958 358 367
55. I. Willett, M. Esler, F. Burke, P. Leonard, and F. Dudley Total and renal sympathetic nervous system activity in alcoholic cirrhosis J Hepatol 1 1985 639 648
56. L. Rosoff Jr., J. Williams, P. Moult, H. Williams, and S. Sherlock Renal hemodynamics and the renin-angiotensin system in cirrhosis: relationship to sodium retention Dig Dis Sci 24 1979 25 32
57. L. Rosoff Jr., P. Zia, T. Reynolds, and R. Horton Studies of renin and aldosterone in cirrhotic patients with ascites Gastroenterology 69 1975 698 705
58. A. Krag, F. Bendtsen, J.H. Henriksen, and S. Moller Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites Gut 59 2010 105 110
59. J. Llach, P. Gines, V. Arroyo, A. Rimola, L. Tito, and S. Badalamenti et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites Gastroenterology 94 1988 482 487
60. B.A. Runyon Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis Gastroenterology 91 1986 1343 1346
61. V. Arroyo, C. Terra, and P. Gines Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome J Hepatol 46 2007 935 946
62. P. Angeli, R. Volpin, D. Piovan, A. Bortoluzzi, R. Craighero, and S. Bottaro et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites Hepatology 28 1998 937 943
63. G. Kalambokis, A. Fotopoulos, M. Economou, K. Pappas, and E.V. Tsianos Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites J Hepatol 46 2007 213 221
64. F. Wong, L. Pantea, and K. Sniderman Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome Hepatology 40 2004 55 64
65. D. McTavish, and K.L. Goa Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders Drugs 38 1989 757 777
66. V. Singh, S.P. Dhungana, B. Singh, R. Vijayverghia, C.K. Nain, and N. Sharma et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study J Hepatol 56 2012 348 354
67. P. Angeli, R. Volpin, G. Gerunda, R. Craighero, P. Roner, and R. Merenda et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide Hepatology 29 1999 1690 1697
68. E. Esrailian, E.R. Pantangco, N.L. Kyulo, K.Q. Hu, and B.A. Runyon Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome Dig Dis Sci 52 2007 742 748
69. L.J. Wood, S. Goergen, J.R. Stockigt, L.W. Powell, and F.J. Dudley Adverse effects of captopril in treatment of resistant ascites, a state of functional bilateral renal artery stenosis Lancet 2 1985 1008 1009
70. M. Schepke, E. Werner, E. Biecker, P. Schiedermaier, J. Heller, and M. Neef et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension Gastroenterology 121 2001 389 395
71. J. Gonzalez-Abraldes, A. Albillos, R. Banares, L.R. Del Arbol, E. Moitinho, and C. Rodriguez et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis Gastroenterology 121 2001 382 388
72. D. Tripathi, G. Therapondos, H.F. Lui, N. Johnston, D.J. Webb, and P.C. Hayes Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis Am J Gastroenterol 99 2004 390 394
73. B.A. Runyon Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012 Hepatology 57 2013 1651 1653
74. B.A. Runyon AASLD PRACTICE GUIDELINE management of adult patients with ascites due to cirrhosis: update 2012 Hepatology 2013 http://www.aasld.org/ practiceguidelines/Documents/ascitesupdate2013.pdf
75. European Association for the Study of the Liver EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis J Hepatol 53 2010 397 417
76. E.H. Forrest, I.A. Bouchier, and P.C. Hayes Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis J Hepatol 25 1996 909 915
77. R. Banares, E. Moitinho, B. Piqueras, M. Casado, J.C. Garcia-Pagan, and A. de Diego et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis Hepatology 30 1999 79 83
78. R. Banares, E. Moitinho, A. Matilla, J.C. Garcia-Pagan, J.L. Lampreave, and C. Piera et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis Hepatology 36 2002 1367 1373
79. D. Tripathi, J.W. Ferguson, N. Kochar, J.A. Leithead, G. Therapondos, and N.C. McAvoy et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed Hepatology 50 2009 825 833
80. J. Bosch Carvedilol for portal hypertension in patients with cirrhosis Hepatology 51 2010 2214 2218
81. Q. Che, M.J. Schreiber Jr., and M.A. Rafey Beta-blockers for hypertension: are they going out of style? Cleve Clin J Med 76 2009 533 542
82. S. Balamuthusamy, J. Molnar, S. Adigopula, and R. Arora Comparative analysis of beta-blockers with other antihypertensive agents on cardiovascular outcomes in hypertensive patients with diabetes mellitus: a systematic review and meta-analysis Am J Ther 16 2009 133 142
83. G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, and G. Germano et al. 2007 Guidelines for the management of arterial hypertension: he Task Force for the Management of ArteTrial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 28 2007 1462 1536
84. C. Rosendorff, H.R. Black, C.P. Cannon, B.J. Gersh, J. Gore, and J.L. Izzo Jr. et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Circulation 115 2007 2761 2788
85. P.J. Devereaux, H. Yang, S. Yusuf, G. Guyatt, K. Leslie, and J.C. Villar et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial Lancet 371 2008 1839 1847
86. F. Wong, and F. Salerno Beta-blockers in cirrhosis: friend and foe? Hepatology 52 2010 811 813
87. A. Gines, G. Fernandez-Esparrach, A. Monescillo, C. Vila, E. Domenech, and R. Abecasis et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis Gastroenterology 111 1996 1002 1010
88. C. Bataille, E. Bercoff, E.A. Pariente, D. Valla, and D. Lebrec Effects of propranolol on renal blood flow and renal function in patients with cirrhosis Gastroenterology 86 1984 129 133
89. D. Lebrec, P. Hillon, C. Munoz, G. Goldfarb, O. Nouel, and J.P. Benhamou The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study Hepatology 2 1982 523 527
90. J. Vorobioff, E. Picabea, R. Villavicencio, V. Puccini, O. Rossi, and J. Bordato et al. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients Hepatology 7 1987 648 653
91. C. Villanueva, J. Minana, J. Ortiz, A. Gallego, G. Soriano, and X. Torras et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding N Engl J Med 345 2001 647 655
92. C. Merkel, M. Bolognesi, D. Sacerdoti, G. Bombonato, B. Bellini, and R. Bighin et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis Hepatology 32 2000 930 934
93. A. Albillos, R. Banares, M. Gonzalez, C. Ripoll, R. Gonzalez, and M.V. Catalina et al. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis Am J Gastroenterol 102 2007 1116 1126
94. A. Stoudemire, and T.L. Thompson 2nd Medication noncompliance: systematic approaches to evaluation and intervention Gen Hosp Psychiatry 5 1983 233 239
95. F. Kanwal, J.R. Kramer, P. Buchanan, S.M. Asch, Y. Assioun, and B.R. Bacon et al. The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs Gastroenterology 143 2012 70 77
96. G. Sharma, K.E. Fletcher, D. Zhang, Y.F. Kuo, J.L. Freeman, and J.S. Goodwin Continuity of outpatient and inpatient care by primary care physicians for hospitalized older adults JAMA 301 2009 1671 1680
97. F. Morando, G. Maresio, S. Piano, S. Fasolato, M. Cavallin, and A. Romano et al. How to improve care in outpatients with cirrhosis and ascites: a new model of care coordination by consultant hepatologists J Hepatol 59 2003 257 264
98. B.A. Runyon, S. Squier, and M. Borzio Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis J Hepatol 21 1994 792 796
99. Z. Ma, and S.S. Lee Cirrhotic cardiomyopathy: getting to the heart of the matter Hepatology 24 1996 451 459
100. G.H. Lo, W.C. Chen, M.H. Chen, P.I. Hsu, C.K. Lin, and W.L. Tsai et al. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding Gastroenterology 123 2002 728 734